The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
A YKL-40–Neutralizing Antibody Blocks Tumor Angiogenesis and Progression: A Potential Therapeutic Agent in Cancers
Open accessAbstract
Accumulating evidence has indicated that expression levels of YKL-40, a secreted glycoprotein, were elevated in multiple advanced human cancers. Recently, we have identified an angiogenic role of YKL-40 in cancer development. However, blockade of the function of YKL-40, which implicates therapeutic value, has not been explored yet. Our current study sought to establish a monoclonal anti–YKL-40 antibody as a neutralizing antibody for the purpose of blocking tumor angiogenesis and metastasis. A mouse monoclonal anti–YKL-40 antibody (mAY) exhibited specific binding with recombinant YKL-40 and with YKL-40 secreted from osteoblastoma cells MG-63 and brain tumor cells U87. In the functional analysis, we found that mAY inhibited tube formation of microvascular endothelial cells in Matrigel induced by conditioned medium of MG-63 and U87 cells, as well as recombinant YKL-40. mAY also abolished YKL-40–induced activation of the membrane receptor VEGF receptor 2 (Flk-1/KDR) and intracellular signaling mitogen-activated protein (MAP) kinase extracellular signal–regulated kinase (Erk) 1 and Erk 2. In addition, mAY enhanced cell death response of U87 line to γ-irradiation through decreased expression of pAKT and AKT and accordingly, abrogated angiogenesis induced by the conditioned medium of U87 cells in which YKL-40 levels were elevated by treatment with γ-irradiation. Furthermore, treatment of xenografted tumor mice with mAY restrained tumor growth, angiogenesis, and progression. Taken together, this study has shown the therapeutic use for the mAY in treatment of tumor angiogenesis and metastasis. Mol Cancer Ther; 10(5); 742–51. ©2011 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tumorigenesis and the angiogenic switch
Bergers, G., & Benjamin, L. E. (2003) · Nature reviews. Cancer · doi:10.1038/nrc1093 · Cited by 3,559
VEGF and the quest for tumour angiogenesis factors
Ferrara, N. (2002) · Nature Reviews Cancer · doi:10.1038/nrc909 · Cited by 1,536
Cited by
Role of tumor associated macrophages in tumor angiogenesis and lymphangiogenesis
Riabov, V., Gudima, A., Wang, N., Mickley, A., Orekhov, A., & Kzhyshkowska, J. (2014) · Frontiers in Physiology · doi:10.3389/fphys.2014.00075 · Cited by 628
Chitinase-3 like-protein-1 function and its role in diseases
Zhao, T., Su, Z., Li, Y., Zhang, X., & You, Q. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00303-7 · Cited by 536
Role of YKL-40 in the Angiogenesis, Radioresistance, and Progression of Glioblastoma
Francescone, R. A., Scully, S., Faibish, M., Taylor, S. L., Oh, D., Moral, L., Yan, W., Bentley, B., & Shao, R. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.212514 · Cited by 261
Self-citationSignificance of chitinase-3-like protein 1 in the pathogenesis of inflammatory diseases and cancer
Yu, J. E., Yeo, I. J., Han, S.-B., Yun, J., Kim, B., Yong, Y. J., Lim, Y.-S., Kim, T. H., Son, D. J., & Hong, J. T. (2024) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-01131-9 · Cited by 109
Metadata
- Authors
- Faibish, M., Francescone, R., Bentley, B., Yan, W., & Shao, R.
- Venue
- Molecular Cancer Therapeutics
- Published
- 2011-05-01
- Volume
- 10
- Issue
- 5
- Pages
- 742-751
- ISSN
- 1535-7163 (ISSN-L)
- 1538-8514
- OpenAlex
- W2159057646
- Cited by
- 181
- References
- 2
- FWCI
- 4.82
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A YKL-40–Neutralizing Antibody Blocks Tumor Angiogenesis and Progression: A Potential Therapeutic Agent in Cancers. https://app.cochat.ai/papers/10.1158/1535-7163.mct-10-0868
- The paper
- Faibish, M., Francescone, R., Bentley, B., Yan, W., & Shao, R. (2011). A YKL-40–Neutralizing Antibody Blocks Tumor Angiogenesis and Progression: A Potential Therapeutic Agent in Cancers. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-10-0868
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.